SUN PHARMA ADVANCED RESEARCH COMPANY
|
SUN PHARMA ADVANCED RESEARCH COMPANY Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -11.96 | -6.86 | -7.48 | -5.77 | -11.92 |
| CEPS(Rs) | -11.59 | -6.50 | -7.11 | -5.35 | -11.56 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 3.85 | 15.80 | -7.47 | -6.42 | -0.71 |
| Tax Rate(%) | - | - | - | - | - |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -534.50 | -89.65 | -136.07 | -53.36 | -403.58 |
| EBIT Margin(%) | -511.55 | -90.02 | -138.48 | -55.54 | -403.22 |
| Pre Tax Margin(%) | -513.74 | -93.22 | -148.19 | -59.75 | -406.70 |
| PAT Margin (%) | -513.74 | -93.22 | -148.19 | -59.75 | -406.70 |
| Cash Profit Margin (%) | -497.68 | -88.29 | -140.79 | -55.43 | -394.36 |
| Performance Ratios | |||||
| ROA(%) | -58.96 | -40.10 | -79.80 | -60.18 | -93.11 |
| ROE(%) | -121.73 | -143.72 | - | - | -225.08 |
| ROCE(%) | -112.88 | -69.44 | -225.57 | -254.10 | -178.95 |
| Asset Turnover(x) | 0.11 | 0.43 | 0.54 | 1.01 | 0.23 |
| Sales/Fixed Asset(x) | 0.51 | 1.71 | 1.07 | 1.96 | 0.71 |
| Working Capital/Sales(x) | 29.99 | 0.87 | -1.37 | -1.46 | -0.46 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.97 | 0.58 | 0.93 | 0.51 | 1.40 |
| Receivable days | 116.55 | 46.20 | 60.25 | 24.26 | 62.28 |
| Inventory Days | - | - | - | - | - |
| Payable days | - | - | - | - | - |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -31.93 | -27.62 | -41.77 | -26.48 | -8.35 |
| Price/Book(x) | 96.16 | 11.36 | -39.75 | -22.07 | -135.68 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 157.49 | 23.92 | 59.34 | 15.55 | 33.79 |
| EV/Core EBITDA(x) | -31.79 | -28.11 | -45.27 | -30.37 | -8.64 |
| EV/EBIT(x) | -30.79 | -26.57 | -42.85 | -28.01 | -8.38 |
| EV/CE(x) | 69.23 | 11.14 | 29.08 | 17.13 | 9.52 |
| M Cap / Sales | 158.92 | 24.39 | 58.81 | 14.68 | 32.92 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -68.36 | 73.98 | -45.74 | 229.31 | -57.99 |
| Core EBITDA Growth(%) | -84.23 | -12.94 | -38.85 | 56.85 | -117.91 |
| EBIT Growth(%) | -79.79 | -13.09 | -35.29 | 54.64 | -113.11 |
| PAT Growth(%) | -74.36 | -9.43 | -34.58 | 51.62 | -114.81 |
| EPS Growth(%) | -74.37 | 8.32 | -29.71 | 51.62 | -114.81 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.38 | - | -0.37 | -1.37 | -3.59 |
| Current Ratio(x) | 1.01 | 2.54 | 0.42 | 0.26 | 0.29 |
| Quick Ratio(x) | 1.01 | 2.54 | 0.42 | 0.26 | 0.29 |
| Interest Cover(x) | -233.48 | -28.15 | -14.26 | -13.19 | -115.79 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.06 | 0.03 |
Compare Financial Ratios of peers of SUN PHARMA ADVANCED RESEARCH COMPANY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMA ADVANCED RESEARCH COMPANY | ₹6,632.8 Cr | 3.7% | -1.6% | -23.3% | Stock Analytics | |
| SYNGENE INTERNATIONAL | ₹34,996.6 Cr | 0.9% | 3.6% | 15.5% | Stock Analytics | |
| LATENT VIEW ANALYTICS | ₹9,180.3 Cr | -2.3% | -2.4% | 5.6% | Stock Analytics | |
| JUST DIAL | ₹9,129.1 Cr | -0.9% | -3.3% | 50.2% | Stock Analytics | |
| DREAMFOLKS SERVICES | ₹2,227.5 Cr | -1.9% | -5.5% | -25.3% | Stock Analytics | |
| EKI ENERGY SERVICES | ₹696.9 Cr | 10.5% | -10.1% | -49.4% | Stock Analytics | |
SUN PHARMA ADVANCED RESEARCH COMPANY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMA ADVANCED RESEARCH COMPANY | 3.7% |
-1.6% |
-23.3% |
| SENSEX | 1.8% |
-2.5% |
19.9% |
You may also like the below Video Courses
